Data from PLZF Confers Effector Functions to Donor T Cells That Preserve Graft-versus-Tumor Effects while Attenuating GVHD
Year: 2023
Type: other
Abstract: Efforts to limit GVHD mediated by alloreactive donor T cells after allogeneic bone marrow transplantation are limited by a concomitant decrease in graft-versus-tumor (GVT) activity and increased possibilities of tumor relapse. Using a novel approach, we adoptively transferred conventional T cells expressing the transcription factor promyelocytic leukemia zinc finger (PLZF), which confers effector properties resembling invariant natural killer T cells, such as copious production of cytokines under suboptimal stimulation. PLZF expression in T-cell allografts attenuates expansion of alloreactive T cells, leading to lower GVHD. Intact alloreactivity-driven antitumor cytokine responses result in preserved GVT effects, leading to improved survival. Our findings suggest that therapy with PLZF-overexpressing T cells would result in overall improved outcomes due to less GVHD and intact GVT effects. Cancer Res; 73(15); 4687–96. ©2013 AACR.
Authors: Arnab Ghosh, Amanda M. Holland, Yildirim Dogan, Nury L. Yim, Uttam K. Rao, Lauren F. Young, Mallory L. West, Natalie V. Singer, Hae Lee, Il-Kang Na, Jennifer J. Tsai, Robert R. Jenq, Olaf Penack, Alan M. Hanash, Cecilia Lezcano, George F. Murphy, Chen Liu, Michel Sadelain, Martin G. Sauer, Derek Sant'Angelo, Marcel R.M. van den Brink
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392679960